Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verve Therapeutics Inc VERV

Healthcare Biotechnology
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering... see more

Recent & Breaking News (NDAQ:VERV)

Levi & Korsinsky Notifies Shareholders of Verve Therapeutics, Inc.(VERV) of a Class Action Lawsuit and an Upcoming Deadline

Accesswire September 18, 2024

VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Accesswire September 18, 2024

Lost Money on Verve Therapeutics, Inc.(VERV)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Accesswire September 17, 2024

Investors in Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

Accesswire September 17, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc. - VERV

PR Newswire September 17, 2024

Contact Levi & Korsinsky by October 28, 2024 Deadline to Join Class Action Against Verve Therapeutics, Inc.(VERV)

Accesswire September 17, 2024

ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - VERV

Newsfile September 17, 2024

October 28, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VERV

Accesswire September 17, 2024

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics Lawsuit - VERV

Accesswire September 17, 2024

Verve Therapeutics Inc May Have Violated Securities Regulations And Shareholders With Losses Should Contact The Schall Law Firm

Accesswire September 17, 2024

Verve Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

Accesswire September 17, 2024

VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

Accesswire September 17, 2024

Shareholders that lost money on Verve Therapeutics, Inc.(VERV) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

PR Newswire September 17, 2024

Verve Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV

Accesswire September 16, 2024

ROSEN, A RESPECTED AND LEADING FIRM, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - VERV

Newsfile September 16, 2024

Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - VERV

Accesswire September 16, 2024

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics

Newsfile September 16, 2024

Verve Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - VERV

Accesswire September 16, 2024

The Schall Law Firm Urges Investor Participation In A Securities Fraud Case Against Verve Therapeutics, Inc.

Accesswire September 16, 2024

Levi & Korsinsky Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV

Accesswire September 16, 2024